Compare AbbVie Inc (ABBV) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Corsair Gaming Inc — how do they compare? AbbVie Inc trades at $249.52 (market cap $441.94B), while Corsair Gaming Inc trades at $12.72 (market cap $1.39B). The key difference: AbbVie Inc is far larger — about 317.9× Corsair Gaming Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals.
| ABBV | CRSR | |
|---|---|---|
Market Cap | $441.94B | $1.39B |
Sector | Health | Technology |
52-Week High | $263.58 | $14.35 |
52-Week Low | $197.38 | $4.58 |
Enterprise Value | $506.19B | $1.38B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Corsair Gaming (CRSR) trades at $13.71, down 4.46% today, but maintains a bullish technical outlook with strong moving average signals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.23 significantly exceeding the $0.07 estimate. Recent acquisitions and AI product launches, including the Trak Racer asset purchase and Stream Deck AI integration, highlight strategic growth initiatives. However, the stock faces valuation concerns with a P/E ratio of 41.39 and negative net income in 2025.
The outlook remains cautiously optimistic with improving profitability projected for 2026 (2.53% net margin) and strong analyst support (36% buy ratings). Key risks include competitive pressures in gaming hardware and inconsistent cash flow generation. The current price sits near key support at $13, with upside potential to the $15 consensus target if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
